Product Description References1. Sorensen, S.M., Kehne, J.H., Fadayel, G.M., et al. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther. 266(2), (1993).
2. Kehne, J.H., Baron, B.M., Carr, A.A., et al. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 277(2), (1996).
3. Pehek, E.A., Nocjar, C., Roth, B.L., et al. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 31(2), (2006).
4. Ardayfio, P.A., Benvenga, M.J., Chaney, S.F., et al. The 5-hydroxytryptamine2A receptor antagonist R-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of differential-reinforcement-of-low-rate 72-s behavior in the rat. J. Pharmacol. Exp. Ther. 327(3), (2008).
5. Boothman, L.J., Mitchell, S.N., and Sharp, T. Investigation of the SSRI augmentation properties of 5-HT2 receptor antagonists using in vivo microdialysis. Neuropharmacology 50(6), (2006).